A Randomized, Controlled Study to Evaluate the Sensitizing Potential of LEO 43204 Gel and Gel Vehicle in Healthy Volunteers Using a Repeat Insult Patch Test Design
Phase of Trial: Phase I
Latest Information Update: 08 May 2017
At a glance
- Drugs Ingenol disoxate (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- Sponsors LEO Pharma
- 19 Aug 2016 Status changed from recruiting to completed.
- 10 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 06 Feb 2016 New trial record